sirolimus

Type: Keyphrase
Name: sirolimus
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Findings from Pasteur Institute Broaden Understanding of Transplantation Research

(NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Data detailed on Transplantation Research have been presented. According to news reporting originating from Paris, France, by NewsRx correspondents, research stated, "In this ancillary ... [Published NewsRX - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 2 reports

Patients with Rare Lung Disease Face Agonizing Treatment Dilemma

(Loyola University Health System) The drug sirolimus can slow progression of the lung disease LAM, while also causing potentially fatal complications in lung transplant patients. But research suggests a drug similar to sirolimus may be safe for LAM patients ... [Published Infrosoft - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Patients with rare lung disease face agonizing treatment dilemma

( Loyola University Health System ) The drug sirolimus can slow progression of the lung disease LAM, while also causing potentially fatal complications in lung transplant patients. But research suggests a drug similar to sirolimus may be safe for LAM ... [Published Infrosoft - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 2 reports

SANTEN PHARMACEUTICAL : Phase III Study Meets Primary Endpoint for the Treatment of Non-Infectious Posterior Segment Uveitis NI-PSU

By a News Reporter-Staff News Editor at Pharma Business Week -- Santen Inc. , the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. ( Osaka, Japan ), announced that SAKURA (Study Assessing double-masKed Uveitis ... [Published 4 Traders - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Implantable sensor with biocompatible coating for controlling or inhibiting tissue growth

All or a portion of a surface of an implantable sensor is covered with a biocompatible coating formed at least partially of a biomaterial matrix having properties that promote a substantially even growth of tissue cells over the surface of the coating. ... [Published Free Patents Online - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

Research and Markets: US Therapeutic Drug Monitoring (TDM) Market 2014: Hospitals, Commercial Labs, Physician Offices

Research and Markets ( http://www.researchandmarkets.com/research/mqlm5q/us_therapeutic )has announced the addition of the "USTherapeutic Drug Monitoring (TDM) Market 2014: Hospitals, CommercialLabs, Physician Offices" report to their offering.This new ... [Published 4 Traders - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Phase 3 study of sirolimus for posterior segment uveitis achieves primary endpoint

Santen Inc. announced that its first of two global phase 3 studies analyzing the efficacy and safety of intravitreal injections of sirolimus in  noninfectious posterior segment uveitis patients has met its primary endpoint.The Study Assessing Double‐Masked ... [Published Orthopedics Today - Apr 09 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Transplant Drugs May Help Reduce HIV Persistence

Red Orbit reported on research suggesting that anti-rejection drugs used after transplantation may help fight HIV. The virus remains hidden in the immune system even though patients are adhering to the antiretroviral treatment regimen. The drugs cannot ... [Published The Body PRO - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 05 2014 - 2 reports

Intravitreal Sirolimus Meets Phase III Goal as Uveitis Therapy

Study tests nonsteroidal alternative to current treatmentsSAKURA ( S tudy A ssessing Double-Mas K ed U veitis T R e A tment) Study 1, the first of two global phase III trials evaluating intravitreal injections of sirolimus (Santen Inc.) in patients with ... [Published P&T Community - Apr 05 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 3 reports

Transplant drugs may help defeat HIV

By Sally Robertson , BScDrugs that are currently given to prevent organ rejection in patients who have received a transplant may offer a new approach to curing HIV, say researchers.In a study of HIV patients who underwent kidney transplant , drugs that ... [Published News-Medical.Net - Apr 03 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 2 reports

Patient Enrollment Completed in Multicenter European REMEDEE Registry of OrbusNeich's COMBO Dual Therapy Stent™

/PRNewswire/ -- OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo ... [Published BusinessWeek - Mar 28 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 2 reports

Hisun Pharmaceutical Submitted For Sirolimus To China FDA

Related Biotechnology, Pharmaceutical and Healthcare NewsChina FDA has accepted the application Zhejiang Hisun Pharmaceutical Co. Ltd. for a Class 3.1 drug, sirolimus, as both a chemical API drug and an injectable drug.Original Article: NEXT ARTICLE ... [Published BioPortfolio - Mar 21 2014]

Quotes

...According to news reporting originating from Paris, France, by NewsRx correspondents, research stated, "In this ancillary study of the CONCEPT trial, we studied the role of CsA withdrawal at 3months (3M) post-transplant on the intensity of epithelial phenotypic changes (EPC, an early marker for kidney fibrogenesis) on the 12M surveillance biopsy. Although conversion from CsA to sirolimus (SRL) at 3M was reported to have improved mean graft function at 12M, it did not reduce the score of EPC (1.73 +/- 1.15 in the SRL group vs. 1.87 +/- 1... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."
Dr. Povlishock continues, "While the authors strike the appropriate cautionary notes in terms of sample size and other limitations, these extremely important prospective observational studies should clearly inform decision-making processes in current and future military populations who have sustained such injuries."
..."One of the frustrations of having a rare disease is that there has not been a lot of work in this area," Lentz said. "There are more unknowns than if this were a common disease."
"NI-PSU is a debilitating disease which affects working-aged adults worldwide. Currently, there are no FDA approved non-steroidal treatments for this sight threatening condition. We are excited by the SAKURA data and believe sirolimus may provide physicians with the first non-steroidal intravitreal treatment option for their patients suffering with NI-PSU" said Dr. Naveed Shams , Chief Scientific Officer and President & CEO of Santen Inc

More Content

All (84) | News (75) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Findings from Pasteur Institute Broaden Underst... [Published NewsRX - Apr 18 2014]
Patients with rare lung disease face agonizing ... [Published Infrosoft - Apr 17 2014]
Patients with Rare Lung Disease Face Agonizing ... [Published Infrosoft - Apr 17 2014]
Patients with rare lung disease face agonizing... [Published EurekAlert! - Apr 17 2014]
SANTEN PHARMACEUTICAL : Phase III Study Meets P... [Published 4 Traders - Apr 17 2014]
Santen's Phase III eye disorder study meets pri... [Published Individual.com - Apr 16 2014]
Tacrolimus for improved treatment of transplant... [Published PharmCast - Apr 16 2014]
Implantable sensor with biocompatible coating f... [Published Free Patents Online - Apr 15 2014]
AB SCIEX Announces Immunosuppressants Kit for U... [Published Select Science - Apr 14 2014]
Research and Markets: US Therapeutic Drug Monit... [Published 4 Traders - Apr 10 2014]
US Therapeutic Drug Monitoring (TDM) Market 201... [Published Individual.com - Apr 10 2014]
Phase 3 study of sirolimus for posterior segmen... [Published Orthopedics Today - Apr 09 2014]
Combination therapy [Published Free Patents Online - Apr 08 2014]
AB SCIEX Highlights Immunosuppressants Kit [Published Individual.com - Apr 08 2014]
Transplant Drugs May Help Reduce HIV Persistence [Published The Body PRO - Apr 08 2014]
Japan Clinical Chemistry & Immunodiagnostics Ma... [Published PitchEngine - Apr 07 2014]
OrbusNeich completes enrollment in coronary les... [Published Individual.com - Apr 07 2014]
UK Therapeutic Drug Monitoring (TDM) Market 201... [Published PitchEngine - Apr 07 2014]
The new Hamilton MassSTAR [Published MyNewsDesk - Apr 07 2014]
HIV Cure: Transplant Drugs to Replace Antiretro... [Published International Business Times Canada - Apr 07 2014]
Intravitreal Sirolimus Meets Phase III Goal as ... [Published P&T Community - Apr 05 2014]
Santen, Inc. Phase 3 Study Meets Primary Endpoi... [Published BioSpace - Apr 04 2014]
Can a transplant drug help eliminate lingering ... [Published Los Angeles Times - Apr 04 2014]
Santen Phase III Study Meets Primary Endpoint f... [Published CNBC - Apr 04 2014]
Santen Phase III Study Meets Primary Endpoint f... [Published Business Wire Health News - Apr 04 2014]
Transplant drugs may help defeat HIV [Published News-Medical.Net - Apr 03 2014]
Could transplant drugs replace antiretrovirals ... [Published Medical News Today - Apr 03 2014]
Transplant drugs may help wipe out persistent H... [Published Medical Xpress - Apr 03 2014]
Patent Issued for Apparatus and Methods for Loa... [Published HispanicBusiness.com - Apr 02 2014]
Reboot the immune system to avoid transplant re... [Published New Scientist - Apr 02 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Santen Phase III Study Meets Primary Endpoint f... [Published Business Wire Health News - Apr 04 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the ...
Drug Patent Expirations for March 30 2014 [Published Biotech Blog - Mar 30 2014]
Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ...
Patient Enrollment Completed in Multicenter Eur... [Published PR Newswire: Health - Mar 28 2014]
HONG KONG, March 28, 2014 /PRNewswire/ -- OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated ...
Sirolimus Therapy in Infants with Severe Hyperi... [Published The New England Journal of Medicine: Endocrinology - Mar 20 2014]
Hyperinsulinemic hypoglycemia, a major cause of severe hypoglycemia during the neonatal period, is characterized by inappropriate insulin secretion from pancreatic beta cells in the presence of low blood glucose levels. The condition may result from defects ...
Drug Patent Expirations in January 2014 [Published Biotech Blog - Jan 18 2014]
Copyright © thinkBiotech Drug Patent Expirations for January 2014TradenameApplicantGeneric NamePatent NumberPatent Expiration EPIVIR-HBV Glaxosmithkline lamivudine RE39155*PED Jan 2, 2014 MICARDIS Boehringer Ingelheim telmisartan 5,591,762 Jan ...
1 2

Press Releases

sort by: Date | Relevance
Artikel im American Journal of Cardiology zeigt... [Published PR Newswire - Nov 21 2013]
Scientific guideline: Draft sirolimus product-s... [Published EMA Ongoing public consultations - Nov 15 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.